Femasys Inc
FEMY0.835USD
+0.151+22.17%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
27.20MMarket Cap
LossP/E TTM
More Details of Femasys Inc Company
Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Femasys Inc Info
Ticker SymbolFEMY
Company nameFemasys Inc
IPO dateJun 18, 2021
CEOMs. Kathy Lee-Sepsick
Number of employees69
Security typeOrdinary Share
Fiscal year-endJun 18
Address3950 Johns Creek Court
CitySUWANEE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code30024
Phone17705003910
Websitehttps://www.femasys.com/
Ticker SymbolFEMY
IPO dateJun 18, 2021
CEOMs. Kathy Lee-Sepsick
Company Executives of Femasys Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
432.85K
+12.63%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Independent Director
Independent Director
--
--
Mr. Daniel Currie
Mr. Daniel Currie
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
Ms. Christine Thomas
Ms. Christine Thomas
Chief Regulatory and Clinical Officer
Chief Regulatory and Clinical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
432.85K
+12.63%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
409.27K
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 10
Updated: Wed, Sep 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Chernett (Jorey)
7.05%
Dauntless Investment Group, LLC
5.40%
Uzialko (Edward R Jr.)
2.83%
The Vanguard Group, Inc.
2.21%
Alumni Capital Management LLC
2.17%
Other
80.34%
Shareholders
Shareholders
Proportion
Chernett (Jorey)
7.05%
Dauntless Investment Group, LLC
5.40%
Uzialko (Edward R Jr.)
2.83%
The Vanguard Group, Inc.
2.21%
Alumni Capital Management LLC
2.17%
Other
80.34%
Shareholder Types
Shareholders
Proportion
Individual Investor
11.44%
Investment Advisor
10.05%
Investment Advisor/Hedge Fund
3.17%
Research Firm
0.49%
Hedge Fund
0.33%
Bank and Trust
0.04%
Venture Capital
0.04%
Other
74.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
60
6.07M
14.12%
+1.37M
2025Q2
71
8.74M
26.88%
+594.69K
2025Q1
67
7.22M
24.70%
+706.34K
2024Q4
60
4.03M
17.61%
-312.38K
2024Q3
58
3.32M
14.71%
-994.98K
2024Q2
60
3.27M
14.50%
-951.60K
2024Q1
59
3.16M
17.88%
-1.13M
2023Q4
59
3.12M
17.80%
-765.84K
2023Q3
57
3.89M
25.74%
+6.18K
2023Q2
54
3.49M
25.26%
-520.59K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chernett (Jorey)
3.03M
7.05%
+1.41M
+86.81%
Jun 30, 2025
Dauntless Investment Group, LLC
2.32M
5.4%
+745.63K
+47.34%
Jun 30, 2025
Uzialko (Edward R Jr.)
1.22M
2.83%
--
--
Apr 08, 2025
The Vanguard Group, Inc.
951.87K
2.21%
+126.20K
+15.28%
Jun 30, 2025
Alumni Capital Management LLC
931.90K
2.17%
+931.90K
--
Sep 04, 2025
Lee-Sepsick (Kathy)
432.85K
1.01%
+48.53K
+12.63%
Aug 27, 2025
Clear Creek Financial Management, LLC
281.82K
0.66%
+11.45K
+4.23%
Jun 30, 2025
Geode Capital Management, L.L.C.
251.39K
0.58%
+5.89K
+2.40%
Jun 30, 2025
CM Management, LLC
225.00K
0.52%
-200.00K
-47.06%
Jun 30, 2025
UBS Financial Services, Inc.
122.33K
0.28%
+122.33K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
